Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 206

1.

Sofosbuvir/Velpatasvir for the treatment of Hepatitis C Virus infection.

Zignego AL, Monti M, Gragnani L.

Acta Biomed. 2018 Oct 8;89(3):321-331. doi: 10.23750/abm.v89i3.7718.

PMID:
30333452
2.

Antiviral therapy in hepatitis C-infected patients prevents relapse of diffuse large B cell lymphoma.

Pellicelli A, Giannelli V, Zoli V, Pellicelli V, Zignego AL.

Clin Exp Hepatol. 2018 Sep;4(3):197-200. doi: 10.5114/ceh.2018.78124. Epub 2018 May 10.

3.

IgG cryoglobulinemia.

Gulli F, Basile U, Gragnani L, Napodano C, Pocino K, Miele L, Santini SA, Zignego AL, Gasbarrini A, Rapaccini GL.

Eur Rev Med Pharmacol Sci. 2018 Sep;22(18):6057-6062. doi: 10.26355/eurrev_201809_15943.

PMID:
30280791
4.

Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN).

Minutolo R, Aghemo A, Chirianni A, Fabrizi F, Gesualdo L, Giannini EG, Maggi P, Montinaro V, Paoletti E, Persico M, Perticone F, Petta S, Puoti M, Raimondo G, Rendina M, Zignego AL; Italian Society of Nephrology (SIN), the Italian Association for the Study of the Liver (AISF), the Italian Society of Infectious and Tropical Disease (SIMIT), the Italian Society of Internal Medicine (SIMI).

Dig Liver Dis. 2018 Nov;50(11):1133-1152. doi: 10.1016/j.dld.2018.08.022. Epub 2018 Sep 12.

PMID:
30266305
5.

Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN).

Minutolo R, Aghemo A, Chirianni A, Fabrizi F, Gesualdo L, Giannini EG, Maggi P, Montinaro V, Paoletti E, Persico M, Perticone F, Petta S, Puoti M, Raimondo G, Rendina M, Zignego AL; Italian Society of Nephrology (SIN); Italian Association for the Study of the Liver (AISF); Italian Society of Infectious and Tropical Disease (SIMIT); Italian Society of Internal Medicine (SIMI).

Intern Emerg Med. 2018 Sep 25. doi: 10.1007/s11739-018-1940-9. [Epub ahead of print]

PMID:
30255464
6.

Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN).

Minutolo R, Aghemo A, Chirianni A, Fabrizi F, Gesualdo L, Giannini EG, Maggi P, Montinaro V, Paoletti E, Persico M, Perticone F, Petta S, Puoti M, Raimondo G, Rendina M, Zignego AL; Italian Society of Nephrology (SIN); Italian Association for the Study of the Liver (AISF); Italian Society of Infectious and Tropical Disease (SIMIT); Italian Society of Internal Medicine (SIMI).

J Nephrol. 2018 Oct;31(5):685-712. doi: 10.1007/s40620-018-0523-1. Epub 2018 Sep 25.

PMID:
30255440
7.

Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN).

Minutolo R, Aghemo A, Chirianni A, Fabrizi F, Gesualdo L, Giannini EG, Maggi P, Montinaro V, Paoletti E, Persico M, Perticone F, Petta S, Puoti M, Raimondo G, Rendina M, Zignego AL; Italian Society of Nephrology (SIN); Italian Association for the Study of the Liver (AISF); Italian Society of Infectious and Tropical Disease (SIMIT); Italian Society of Internal Medicine (SIMI).

Infection. 2018 Sep 25. doi: 10.1007/s15010-018-1209-2. [Epub ahead of print]

PMID:
30255389
8.

Editorial: interferon-free DAAs are a great boon for patients with hepatitis C and cryoglobulinaemia-Authors' reply.

Zignego AL, Lorini S, Gragnani L.

Aliment Pharmacol Ther. 2018 Oct;48(7):772-773. doi: 10.1111/apt.14936. No abstract available.

PMID:
30246308
9.

Cryoglobulinaemia.

Roccatello D, Saadoun D, Ramos-Casals M, Tzioufas AG, Fervenza FC, Cacoub P, Zignego AL, Ferri C.

Nat Rev Dis Primers. 2018 Aug 2;4(1):11. doi: 10.1038/s41572-018-0009-4. Review.

PMID:
30072738
10.

Interferon-free therapy in hepatitis C virus mixed cryoglobulinaemia: a prospective, controlled, clinical and quality of life analysis.

Gragnani L, Cerretelli G, Lorini S, Steidl C, Giovannelli A, Monti M, Petraccia L, Sadalla S, Urraro T, Caini P, Xheka A, Simone A, Arena U, Matucci-Cerinic M, Vergani D, Laffi G, Zignego AL.

Aliment Pharmacol Ther. 2018 Jun 28. doi: 10.1111/apt.14845. [Epub ahead of print]

PMID:
29952013
11.

Forecasting Hepatitis C liver disease burden on real-life data. Does the hidden iceberg matter to reach the elimination goals?

Kondili LA, Robbins S, Blach S, Gamkrelidze I, Zignego AL, Brunetto MR, Raimondo G, Taliani G, Iannone A, Russo FP, Santantonio TA, Zuin M, Chessa L, Blanc P, Puoti M, Vinci M, Erne EM, Strazzabosco M, Massari M, Lampertico P, Rumi MG, Federico A, Orlandini A, Ciancio A, Borgia G, Andreone P, Caporaso N, Persico M, Ieluzzi D, Madonia S, Gori A, Gasbarrini A, Coppola C, Brancaccio G, Andriulli A, Quaranta MG, Montilla S, Razavi H, Melazzini M, Vella S, Craxì A; PITER Collaborating Group.

Liver Int. 2018 Jun 14. doi: 10.1111/liv.13901. [Epub ahead of print]

PMID:
29900654
12.

Epidemiological, demographic and clinical data on chronic viral hepatitis C in Tuscany.

Stasi C, Silvestri C, Berni R, Rossana Brunetto M, Zignego AL, Orsini C, Milani S, Ricciardi L, De Luca A, Blanc P, Nencioni C, Aquilini D, Bartoloni A, Bresci G, Marchi S, Filipponi F, Colombatto P, Forte P, Galli A, Luchi S, Chigiotti S, Nerli A, Corti G, Sacco R, Carrai P, Ricchiuti A, Giusti M, Almi P, Cozzi A, Carloppi S, Laffi G, Voller F, Cipriani F.

Curr Med Res Opin. 2018 Jun 26:1-6. doi: 10.1080/03007995.2018.1482264. [Epub ahead of print]

PMID:
29847179
13.

Clinical epidemiology of chronic viral hepatitis B: A Tuscany real-word large-scale cohort study.

Stasi C, Silvestri C, Berni R, Brunetto MR, Zignego AL, Orsini C, Milani S, Ricciardi L, De Luca A, Blanc P, Nencioni C, Aquilini D, Bartoloni A, Bresci G, Marchi S, Filipponi F, Colombatto P, Forte P, Galli A, Luchi S, Chigiotti S, Nerli A, Corti G, Sacco R, Carrai P, Ricchiuti A, Giusti M, Almi P, Cozzi A, Carloppi S, Laffi G, Voller F, Cipriani F.

World J Hepatol. 2018 May 27;10(5):409-416. doi: 10.4254/wjh.v10.i5.409.

14.

Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis.

Ascione A, De Luca M, Melazzini M, Montilla S, Trotta MP, Petta S, Puoti M, Sangiovanni V, Messina V, Bruno S, Izzi A, Villa E, Aghemo A, Zignego AL, Orlandini A, Fontanella L, Gasbarrini A, Marzioni M, Giannini EG, Craxì A; ABACUS Study Group.

Infection. 2018 Oct;46(5):607-615. doi: 10.1007/s15010-018-1157-x. Epub 2018 May 28.

PMID:
29808463
15.

Different biochemical patterns in type II and type III mixed cryoglobulinemia in HCV positive patients.

Basile U, Gulli F, Gragnani L, Pocino K, Napodano C, Miele L, Santini SA, Marino M, Zignego AL, Rapaccini GL.

Dig Liver Dis. 2018 Sep;50(9):938-943. doi: 10.1016/j.dld.2018.03.028. Epub 2018 Apr 4.

PMID:
29709461
16.

Direct medical costs associated with the extrahepatic manifestations of hepatitis C infection in Europe.

Cacoub P, Buggisch P, Carrión JA, Cooke GS, Zignego AL, Beckerman R, Younossi Z.

J Viral Hepat. 2018 Jul;25(7):811-817. doi: 10.1111/jvh.12881. Epub 2018 Mar 30.

PMID:
29476572
17.

Correction: Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study.

Kondili LA, Gaeta GB, Ieluzzi D, Zignego AL, Monti M, Gori A, Soria A, Raimondo G, Filomia R, Di Leo A, Iannone A, Massari M, Corsini R, Gulminetti R, Gatti Comini A, Toniutto P, Dissegna D, Russo FP, Zanetto A, Rumi MG, Brancaccio G, Danieli E, Brunetto MR, Weimer LE, Quaranta MG, Vella S, Puoti M.

PLoS One. 2018 Jan 2;13(1):e0190803. doi: 10.1371/journal.pone.0190803. eCollection 2018.

18.

Current and future challenges in HCV: insights from an Italian experts panel.

Andreoni M, Babudieri S, Bruno S, Colombo M, Zignego AL, Di Marco V, Di Perri G, Perno CF, Puoti M, Taliani G, Villa E, Craxì A.

Infection. 2018 Apr;46(2):147-163. doi: 10.1007/s15010-017-1093-1. Epub 2017 Nov 2. Review.

PMID:
29098647
19.

Notch4 and mhc class II polymorphisms are associated with hcv-related benign and malignant lymphoproliferative diseases.

Gragnani L, Fognani E, De Re V, Libra M, Garozzo A, Caini P, Cerretelli G, Giovannelli A, Lorini S, Monti M, Bagnoli S, Piaceri I, Zignego AL.

Oncotarget. 2017 May 6;8(42):71528-71535. doi: 10.18632/oncotarget.17655. eCollection 2017 Sep 22.

20.

Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network.

Kondili LA, Gaeta GB, Brunetto MR, Di Leo A, Iannone A, Santantonio TA, Giammario A, Raimondo G, Filomia R, Coppola C, Amoruso DC, Blanc P, Del Pin B, Chemello L, Cavalletto L, Morisco F, Donnarumma L, Rumi MG, Gasbarrini A, Siciliano M, Massari M, Corsini R, Coco B, Madonia S, Cannizzaro M, Zignego AL, Monti M, Russo FP, Zanetto A, Persico M, Masarone M, Villa E, Bernabucci V, Taliani G, Biliotti E, Chessa L, Pasetto MC, Andreone P, Margotti M, Brancaccio G, Ieluzzi D, Borgia G, Zappulo E, Calvaruso V, Petta S, Falzano L, Quaranta MG, Weimer LE, Rosato S, Vella S, Giannini EG.

PLoS One. 2017 Oct 4;12(10):e0185728. doi: 10.1371/journal.pone.0185728. eCollection 2017.

Supplemental Content

Loading ...
Support Center